<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487200</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2011-002</org_study_id>
    <nct_id>NCT01487200</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, pharmacokinetics and pharmacodynamics
      of FX006 in patients with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a double-blind, randomized, parallel-group, active comparator design. The
      study was conducted in male and female patients ≥35 years of age with symptomatic OA of the
      knee.

      Twenty-four (24) patients with knee OA were randomized (1:1:1:1) and treated with a single IA
      injection of either 10, 40, or 60 mg of FX006 or 40 mg of TCA IR.

      Each patient was evaluated for a total of 6 weeks following a single IA injection. Following
      screening, safety, PK and pharmacodynamics (PD) were evaluated during one (1) 48-hour
      in-patient period (Day -1 to Day 2), two (2) 24-hour in-patient periods (Day 14-15 and Day
      42-43) and seven (7) out-patient visits (Days 3, 4, 5, 8, 22, 29 and 36).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 24-hour Weighted Mean Serum Cortisol</measure>
    <time_frame>Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6)</time_frame>
    <description>The primary pharmacodynamic endpoint was change from baseline (pre-dose) to Day 1-2, Day 14-15 (Week 2) and Day 42-43 (Week 6) in 24-hour weighted mean serum cortisol. This is defined as AUC over the 0-24 hour measurement period divided by 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the Pharmacokinetic Profile of FX006 and TCA IR</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 and 24 hours post dose) and Days 3, 4, 5, 8, 15, 22, 29, 36 and 43</time_frame>
    <description>Concentrations below the limit of quantification of 50 pg/mL were treated as 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Urinary Free Cortisol Excretion</measure>
    <time_frame>Baseline to Days 1-2, Baseline to Days 14-15 (Week 2) and Baseline to Days 42-43 (Week 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 24-hour Urinary Free Cortisol Excretion</measure>
    <time_frame>Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Measured Time Point Post-dose in Morning Serum Cortisol</measure>
    <time_frame>Baseline to Days 2, 3, 4, 5, 8, 14, 15, 22, 29, 36, 42 and 43</time_frame>
    <description>Least square mean difference against TCA IR 40 mg</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>FX006 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3 mL intra-articular (IA) injection Extended-release formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX006 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3 mL intra-articular (IA) injection Extended-release formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX006 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3 mL intra-articular (IA) injection Extended-release formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCA IR (40 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 1 mL intra-articular (IA) injection Immediate-release formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 10 mg</intervention_name>
    <description>single 3 mL IA injection</description>
    <arm_group_label>FX006 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 40 mg</intervention_name>
    <description>single 3 mL IA injection</description>
    <arm_group_label>FX006 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 60 mg</intervention_name>
    <description>single 3 mL IA injection</description>
    <arm_group_label>FX006 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCA IR 40</intervention_name>
    <description>single 1 mL IA injection</description>
    <arm_group_label>TCA IR (40 mg)</arm_group_label>
    <other_name>Kenalog®-40</other_name>
    <other_name>Kenacort-A 40</other_name>
    <other_name>Triamcinolone Acetonide Crystalline Suspension (TAcs)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female &gt;=35 years of age

          -  Diagnosis of unilateral or bilateral OA of the knee for at least 6 months prior to
             Screening with confirmation of OA according to American College of Rheumatology
             Criteria for Classification of Idiopathic OA of the Knee (clinical and radiological)
             based on an X-ray performed within 6 months prior to Screening or during the Screening
             period

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Willingness to abstain from use of the protocol-specified restricted medications

        Main Exclusion Criteria:

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
             amyloidosis

          -  History of arthritides due to crystals (e.g., gout, pseudogout)

          -  History of infection in the index joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint (such as a torn anterior cruciate ligament)

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Oral, inhaled or intranasal corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  History of or active malignancy, with the exception of resected basal cell carcinoma,
             squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
             within 5 years

          -  Insulin-dependent diabetes

          -  History of or active Cushing's syndrome

          -  Any other clinically significant acute or chronic medical conditions (e.g.,
             uncontrolled diabetes)

          -  Skin breakdown at the knee where the injection would take place

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Bodick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>November 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2019</results_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>intra-articular</keyword>
  <keyword>injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study took place at 2 centers, both located in Australia. Enrollment for this study took approximately 1.5 months.</recruitment_details>
      <pre_assignment_details>Subjects were screened for eligibility within 14 days of being randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FX006 10mg</title>
          <description>5 subjects received FX006 10 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P2">
          <title>FX006 40mg</title>
          <description>7 subjects received FX006 40 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P3">
          <title>FX006 60 mg</title>
          <description>7 subjects received FX006 60 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P4">
          <title>TCA IR 40 mg</title>
          <description>5 subjects received commercially available triamcinolone acetonide (40 mg) as a single 1 mL IA injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FX006 10mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B2">
          <title>FX006 40mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B3">
          <title>FX006 60 mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B4">
          <title>TCA IR (40 mg)</title>
          <description>Single 1 mL IA injection</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" lower_limit="36" upper_limit="81"/>
                    <measurement group_id="B2" value="59.3" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="B3" value="64.9" lower_limit="56" upper_limit="79"/>
                    <measurement group_id="B4" value="63" lower_limit="53" upper_limit="76"/>
                    <measurement group_id="B5" value="62.5" lower_limit="36" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 24-hour Weighted Mean Serum Cortisol</title>
        <description>The primary pharmacodynamic endpoint was change from baseline (pre-dose) to Day 1-2, Day 14-15 (Week 2) and Day 42-43 (Week 6) in 24-hour weighted mean serum cortisol. This is defined as AUC over the 0-24 hour measurement period divided by 24</description>
        <time_frame>Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Weighted Mean Serum Cortisol</title>
          <description>The primary pharmacodynamic endpoint was change from baseline (pre-dose) to Day 1-2, Day 14-15 (Week 2) and Day 42-43 (Week 6) in 24-hour weighted mean serum cortisol. This is defined as AUC over the 0-24 hour measurement period divided by 24</description>
          <units>weighted mean serum cortisol (nmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Days 1 to 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" lower_limit="-38.4" upper_limit="38.3"/>
                    <measurement group_id="O2" value="-42.7" lower_limit="-59.2" upper_limit="-19.4"/>
                    <measurement group_id="O3" value="-62.2" lower_limit="-73.2" upper_limit="-46.8"/>
                    <measurement group_id="O4" value="-59.0" lower_limit="-72.6" upper_limit="-38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Days 14 to 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" lower_limit="-37.0" upper_limit="25.5"/>
                    <measurement group_id="O2" value="-33.4" lower_limit="-50.2" upper_limit="-10.9"/>
                    <measurement group_id="O3" value="-49.5" lower_limit="-62.3" upper_limit="-32.4"/>
                    <measurement group_id="O4" value="-19.7" lower_limit="-43.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in BL to Days 42 to 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" lower_limit="-26.2" upper_limit="12.3"/>
                    <measurement group_id="O2" value="-18.0" lower_limit="-32.2" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-11.8" lower_limit="-26.1" upper_limit="5.4"/>
                    <measurement group_id="O4" value="-4.8" lower_limit="-22.7" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterize the Pharmacokinetic Profile of FX006 and TCA IR</title>
        <description>Concentrations below the limit of quantification of 50 pg/mL were treated as 0.</description>
        <time_frame>Day 1 (1, 2, 4, 6, 8, 12 and 24 hours post dose) and Days 3, 4, 5, 8, 15, 22, 29, 36 and 43</time_frame>
        <population>PK population was to include all patients who received study drug and had at least one measurable concentration</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize the Pharmacokinetic Profile of FX006 and TCA IR</title>
          <description>Concentrations below the limit of quantification of 50 pg/mL were treated as 0.</description>
          <population>PK population was to include all patients who received study drug and had at least one measurable concentration</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.941" spread="0.4767"/>
                    <measurement group_id="O2" value="638.447" spread="0.6312"/>
                    <measurement group_id="O3" value="862.574" spread="0.6823"/>
                    <measurement group_id="O4" value="12268.835" spread="1.4681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.058" spread="0.2204"/>
                    <measurement group_id="O2" value="779.819" spread="0.6778"/>
                    <measurement group_id="O3" value="1164.013" spread="0.6772"/>
                    <measurement group_id="O4" value="14243.604" spread="1.5643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.406" spread="0.3637"/>
                    <measurement group_id="O2" value="860.476" spread="0.7088"/>
                    <measurement group_id="O3" value="1251.776" spread="0.7030"/>
                    <measurement group_id="O4" value="16282.659" spread="1.7765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.231" spread="0.4108"/>
                    <measurement group_id="O2" value="814.647" spread="0.7131"/>
                    <measurement group_id="O3" value="1182.925" spread="0.6952"/>
                    <measurement group_id="O4" value="14560.886" spread="1.7754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.298" spread="0.4640"/>
                    <measurement group_id="O2" value="748.962" spread="0.7898"/>
                    <measurement group_id="O3" value="1227.658" spread="0.6245"/>
                    <measurement group_id="O4" value="13543.427" spread="1.7347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.506" spread="0.5331"/>
                    <measurement group_id="O2" value="691.962" spread="0.7456"/>
                    <measurement group_id="O3" value="1127.476" spread="0.7841"/>
                    <measurement group_id="O4" value="10112.863" spread="1.6684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (24 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.764" spread="0.4037"/>
                    <measurement group_id="O2" value="763.568" spread="0.7423"/>
                    <measurement group_id="O3" value="1309.260" spread="0.5869"/>
                    <measurement group_id="O4" value="5421.894" spread="1.5196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (48 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.138" spread="0.3999"/>
                    <measurement group_id="O2" value="743.344" spread="0.7583"/>
                    <measurement group_id="O3" value="1294.042" spread="0.7645"/>
                    <measurement group_id="O4" value="2371.778" spread="1.1844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (72 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.987" spread="0.4904"/>
                    <measurement group_id="O2" value="675.086" spread="0.6930"/>
                    <measurement group_id="O3" value="1270.953" spread="0.7088"/>
                    <measurement group_id="O4" value="1310.061" spread="0.8301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (96 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.533" spread="0.3787"/>
                    <measurement group_id="O2" value="690.857" spread="0.7292"/>
                    <measurement group_id="O3" value="1252.021" spread="0.7097"/>
                    <measurement group_id="O4" value="822.243" spread="0.6002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (168 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.257" spread="0.5638"/>
                    <measurement group_id="O2" value="586.977" spread="0.7574"/>
                    <measurement group_id="O3" value="1070.823" spread="0.6322"/>
                    <measurement group_id="O4" value="235.938" spread="1.0814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (336 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.002" spread="0.5244"/>
                    <measurement group_id="O2" value="365.970" spread="0.7325"/>
                    <measurement group_id="O3" value="718.787" spread="0.5587"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (504 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="238.529" spread="0.7026"/>
                    <measurement group_id="O3" value="521.843" spread="0.4563"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (672 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="189.422" spread="0.6089"/>
                    <measurement group_id="O3" value="369.683" spread="0.4589"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36 (840 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                    <measurement group_id="O3" value="246.176" spread="0.3844"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (1008 hrs post dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="138.660" spread="0.6253"/>
                    <measurement group_id="O3" value="187.435" spread="0.3924"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-hour Urinary Free Cortisol Excretion</title>
        <time_frame>Baseline to Days 1-2, Baseline to Days 14-15 (Week 2) and Baseline to Days 42-43 (Week 6)</time_frame>
        <population>Full Analysis Set (FAS) includes all observations from all patients who received a dose of study drug and provided a baseline observation and at least one post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Urinary Free Cortisol Excretion</title>
          <population>Full Analysis Set (FAS) includes all observations from all patients who received a dose of study drug and provided a baseline observation and at least one post baseline observation.</population>
          <units>nmol/24h</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="-11.1" upper_limit="146.2"/>
                    <measurement group_id="O2" value="-43.8" lower_limit="-63.5" upper_limit="-13.6"/>
                    <measurement group_id="O3" value="-50.1" lower_limit="-67.7" upper_limit="-23.0"/>
                    <measurement group_id="O4" value="-58.5" lower_limit="-75.2" upper_limit="-30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 to 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="-25.3" upper_limit="70.8"/>
                    <measurement group_id="O2" value="-42.4" lower_limit="-59.3" upper_limit="-18.3"/>
                    <measurement group_id="O3" value="-59.0" lower_limit="-72.0" upper_limit="-40.0"/>
                    <measurement group_id="O4" value="-14.7" lower_limit="-43.9" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 to 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="-25.8" upper_limit="56.3"/>
                    <measurement group_id="O2" value="-38.3" lower_limit="-56.1" upper_limit="-13.3"/>
                    <measurement group_id="O3" value="-13.1" lower_limit="-36.7" upper_limit="19.3"/>
                    <measurement group_id="O4" value="-21.3" lower_limit="-46.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total 24-hour Urinary Free Cortisol Excretion</title>
        <time_frame>Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6)</time_frame>
        <population>FAS includes all observations from all patients who received a dose of study drug and provided a baseline observation and at least one post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Total 24-hour Urinary Free Cortisol Excretion</title>
          <population>FAS includes all observations from all patients who received a dose of study drug and provided a baseline observation and at least one post baseline observation.</population>
          <units>nmol/24h</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.66" spread="1.112"/>
                    <measurement group_id="O2" value="29.94" spread="0.770"/>
                    <measurement group_id="O3" value="29.36" spread="0.490"/>
                    <measurement group_id="O4" value="18.77" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 to 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.14" spread="0.842"/>
                    <measurement group_id="O2" value="30.91" spread="0.590"/>
                    <measurement group_id="O3" value="26.46" spread="0.925"/>
                    <measurement group_id="O4" value="36.22" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 to 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.74" spread="0.715"/>
                    <measurement group_id="O2" value="34.62" spread="0.557"/>
                    <measurement group_id="O3" value="51.16" spread="0.499"/>
                    <measurement group_id="O4" value="36.38" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Measured Time Point Post-dose in Morning Serum Cortisol</title>
        <description>Least square mean difference against TCA IR 40 mg</description>
        <time_frame>Baseline to Days 2, 3, 4, 5, 8, 14, 15, 22, 29, 36, 42 and 43</time_frame>
        <population>The full analysis set will include all observations from all patients who received any dose of FX006 and provide a baseline observation and at least one post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>Single 1 mL IA injection of commercially available triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Measured Time Point Post-dose in Morning Serum Cortisol</title>
          <description>Least square mean difference against TCA IR 40 mg</description>
          <population>The full analysis set will include all observations from all patients who received any dose of FX006 and provide a baseline observation and at least one post baseline observation.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" lower_limit="-68.9" upper_limit="57.1"/>
                    <measurement group_id="O2" value="-42.3" lower_limit="-71.1" upper_limit="15.1"/>
                    <measurement group_id="O3" value="-78.2" lower_limit="-89.1" upper_limit="-56.4"/>
                    <measurement group_id="O4" value="-85.4" lower_limit="-93.5" upper_limit="-67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" lower_limit="-61.7" upper_limit="47.5"/>
                    <measurement group_id="O2" value="-40.8" lower_limit="-66.7" upper_limit="5.2"/>
                    <measurement group_id="O3" value="-80.2" lower_limit="-88.9" upper_limit="-64.8"/>
                    <measurement group_id="O4" value="-86.2" lower_limit="-93.0" upper_limit="-72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" lower_limit="-58.1" upper_limit="77.3"/>
                    <measurement group_id="O2" value="-37.1" lower_limit="-66.0" upper_limit="16.4"/>
                    <measurement group_id="O3" value="-77.2" lower_limit="-87.7" upper_limit="-57.8"/>
                    <measurement group_id="O4" value="-73.1" lower_limit="-86.9" upper_limit="-44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" lower_limit="-50.7" upper_limit="55.6"/>
                    <measurement group_id="O2" value="-35.1" lower_limit="-60.3" upper_limit="5.9"/>
                    <measurement group_id="O3" value="-73.0" lower_limit="-83.5" upper_limit="-55.9"/>
                    <measurement group_id="O4" value="-49.8" lower_limit="-71.7" upper_limit="-10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" lower_limit="-50.1" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-37.4" lower_limit="-53.2" upper_limit="-16.1"/>
                    <measurement group_id="O3" value="-61.7" lower_limit="-72.2" upper_limit="-47.4"/>
                    <measurement group_id="O4" value="-8.6" lower_limit="-35.1" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" lower_limit="-37.7" upper_limit="37.1"/>
                    <measurement group_id="O2" value="-35.5" lower_limit="-53.4" upper_limit="-10.7"/>
                    <measurement group_id="O3" value="-40.4" lower_limit="-55.8" upper_limit="-19.6"/>
                    <measurement group_id="O4" value="-27.3" lower_limit="-48.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.4" lower_limit="-48.2" upper_limit="10.4"/>
                    <measurement group_id="O2" value="-28.1" lower_limit="-47.9" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-46.4" lower_limit="-61.2" upper_limit="-26.0"/>
                    <measurement group_id="O4" value="-8.3" lower_limit="-37.2" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="-26.6" upper_limit="45.2"/>
                    <measurement group_id="O2" value="-28.5" lower_limit="-46.5" upper_limit="-4.4"/>
                    <measurement group_id="O3" value="-14.4" lower_limit="-36.0" upper_limit="14.6"/>
                    <measurement group_id="O4" value="-11.3" lower_limit="-36.9" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-26.8" upper_limit="24.5"/>
                    <measurement group_id="O2" value="-21.1" lower_limit="-37.1" upper_limit="-1.1"/>
                    <measurement group_id="O3" value="-6.3" lower_limit="-25.3" upper_limit="17.5"/>
                    <measurement group_id="O4" value="0.8" lower_limit="-22.7" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" lower_limit="-33.5" upper_limit="31.7"/>
                    <measurement group_id="O2" value="-19.5" lower_limit="-39.8" upper_limit="7.7"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-27.6" upper_limit="29.8"/>
                    <measurement group_id="O4" value="11.7" lower_limit="-20.7" upper_limit="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" lower_limit="-47.8" upper_limit="27.7"/>
                    <measurement group_id="O2" value="-27.0" lower_limit="-49.5" upper_limit="5.4"/>
                    <measurement group_id="O3" value="-19.1" lower_limit="-42.4" upper_limit="13.6"/>
                    <measurement group_id="O4" value="-21.4" lower_limit="-47.3" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.1" lower_limit="-39.1" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-14.9" lower_limit="-32.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="-13.4" lower_limit="-29.8" upper_limit="6.9"/>
                    <measurement group_id="O4" value="3.0" lower_limit="-19.5" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from post injection on Day 1 through Day 43.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FX006 10mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="E2">
          <title>FX006 40mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="E3">
          <title>FX006 60 mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="E4">
          <title>TCA IR 40 mg</title>
          <description>Single 1 mL IA injection of commercially available triamcinolone acetonide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Kelley, Chief Medical Officer</name_or_title>
      <organization>Flexion Therapeutics</organization>
      <phone>781-305-7142</phone>
      <email>skelley@flexiontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

